Patents Examined by Umamaheswari Ramachandran
-
Patent number: 11958879Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.Type: GrantFiled: May 19, 2021Date of Patent: April 16, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
-
Patent number: 11958852Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: GrantFiled: August 18, 2021Date of Patent: April 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Patent number: 11951114Abstract: Methods useful for treating X-linked adrenoleukodystrophy are provided.Type: GrantFiled: May 6, 2022Date of Patent: April 9, 2024Assignees: Viking Therapeutics, Inc., Metabasis Therapeutics, Inc.Inventors: Brian Lian, Rochelle Hanley, Misha Dinerman, Mark Erion, Serge Boyer, Hongjian Jiang
-
Patent number: 11937601Abstract: Methods for controlling and/or treating of phytopathogenic fungi causing soybean rust infections in plants include applying a fungicidally effective amount of a composition to the plants, and/or seeds of the plants, or soil in which the plants are growing, or soil in which the plants are desired to grow. The composition includes zoxamide, optionally in combination with one or more additional active ingredients selected from the group consisting of strobilurins and/or triazole compounds. The phytopathogenic fungi are selected from P. pachyrhizi or P. meibomiae. The zoxamide is applied in an amount of about 10 g/ha to about 2000 g/ha.Type: GrantFiled: April 8, 2021Date of Patent: March 26, 2024Assignee: GLOBACHEM NVInventors: Stefaan Reybrouck, Koen Quaghebeur
-
Patent number: 11925629Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: July 6, 2021Date of Patent: March 12, 2024Assignee: ASANA BIOSCIENCES, LLCInventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala
-
Patent number: 11911368Abstract: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and ?-opioid agonistic activity.Type: GrantFiled: November 8, 2019Date of Patent: February 27, 2024Assignee: Supernus Pharmaceuticals, Inc.Inventor: Christopher D. Breder
-
Patent number: 11911395Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.Type: GrantFiled: September 13, 2018Date of Patent: February 27, 2024Assignee: REATA PHARMACEUTICALS HOLDINGS, LLCInventors: Colin J. Meyer, Warren Huff
-
Patent number: 11896717Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.Type: GrantFiled: December 29, 2022Date of Patent: February 13, 2024Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
-
Patent number: 11896598Abstract: An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.Type: GrantFiled: April 29, 2022Date of Patent: February 13, 2024Assignee: RED MOUNTAIN MED SPA, LLCInventor: Suzanne Bentz
-
Patent number: 11890261Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 18, 2021Date of Patent: February 6, 2024Assignee: Adamas Pharmaceuticals, Inc.Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
-
Patent number: 11866440Abstract: Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 28, 2021Date of Patent: January 9, 2024Assignees: CORNELL UNIVERSITY, NOVITA PHARMACEUTICALS, INC.Inventors: Xin-Yun Huang, Christy Young Shue
-
Patent number: 11850225Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.Type: GrantFiled: July 11, 2022Date of Patent: December 26, 2023Assignee: AMNEAL PHARMACEUTICALS LLCInventors: Leonard O'Mahony, Sharon Hamm, John Devane, David Penake, Wolfgang Mohr, Manuel Weinheimer
-
Patent number: 11844775Abstract: A method of treating medium chain acyl-CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, long chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, or CPT II deficiency in a patient is provided comprising administering to the patient a therapeutic amount of a triglyceride or other conjugated fatty acid, that bypasses or leads to an intermediate that bypasses the deficient enzyme. Amino acid-conjugated fatty acids also are provided as well as compositions comprising the amino acid-conjugated fatty acids.Type: GrantFiled: July 11, 2019Date of Patent: December 19, 2023Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Al-Walid A. Mohsen
-
Patent number: 11833121Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 22, 2020Date of Patent: December 5, 2023Assignee: Adamas Pharmaceuticals, Inc.Inventors: Glenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
-
Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone
Patent number: 11826323Abstract: A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.Type: GrantFiled: September 28, 2022Date of Patent: November 28, 2023Assignee: PULMONEM INC.Inventors: Houfar Sekhavat, Satish Asotra -
Patent number: 11819497Abstract: Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.Type: GrantFiled: October 26, 2022Date of Patent: November 21, 2023Assignee: AZURITY PHARMACEUTICALS, INC.Inventor: Hugh Greg Thomas
-
Patent number: 11806338Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.Type: GrantFiled: November 19, 2021Date of Patent: November 7, 2023Assignee: AZURITY PHARMACEUTICALS, INC.Inventor: Hugh Greg Thomas
-
Patent number: 11793776Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 24, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11779554Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 10, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau
-
Patent number: 11771667Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.Type: GrantFiled: March 1, 2023Date of Patent: October 3, 2023Assignee: Axsome Malta Ltd.Inventor: Herriot Tabuteau